Skip to main content
Intended for healthcare professionals
Free access
Editorial
First published online October 15, 2019

Generic Drugs Not as Safe as FDA Wants You to Believe

Abstract

Food and Drug Administration (FDA) rules for the production of prescription drugs are very rigorous and, if followed, guarantees a safe drug supply. For many years, foreign manufacturers have produced substandard generic products and active pharmaceutical ingredients and shipped them into the United States. If the FDA had inspected them with the same rigor as they do domestic manufacturers, they would have found many of these egregious deviations from ethical manufacturing much earlier. Although the FDA is finally stepping up the number of inspections, their current processes still rely on preannounced inspections with long time horizons, so quality issues can be temporarily corrected and documents altered or destroyed.

Background

Generics have been a financial success story for the American patient. Overall, ~90% of prescribed medications in the United States are generics but only account for 26% of drug spending, saving ~$1.7 trillion dollars over the past decade.1 The Food and Drug Administration (FDA) set a new record in 2018, approving 781 new generics.2
When patients are switched from a brand to generic drug or between 2 generics, they sometimes complain of adverse events or state their drug is not working as well. I always attributed this to patient anxiety or happenstance. However, the lack of quality verification of overseas generic manufacturing plants may also be an explanation in some of these cases.
The FDA has strict regulations that, if followed, ensures that generics are of high quality and deliver blood concentrations consistent with brand name products.3 These products can be finished drug products or active pharmaceutical ingredients (APIs; ie, bulk powders) sold to other manufacturers to create finished drug products. Manufacturers must extensively test their products, destroy batches of products that do not adhere to high standards, and have these test results available for inspection. The FDA reviews documents in an abbreviated new drug application to make sure the manufacturer can make a new high-quality finished drug product before giving permission to manufacture it. After that, the FDA does site visits to ensure good manufacturing procedures, adequate testing, and appropriate responses when the tests show quality issues. FDA also does limited spot testing of finished drug products for quality.3
In February 2019, FDA stated unequivocally that generics are safe and effective and outlined the steps that the FDA takes to ensure quality.4

FDA’s Achilles Heel

Approximately 80% of APIs and 40% of the finished pharmaceutical products are no longer manufactured in the United States.5 This poses a major challenge for the FDA because they lack the capacity to adequately oversee foreign manufacturers and struggle with international logistics.
According to the US Government Accountability Office, in 2010, there were 1148 manufacturing plant inspections domestically and 440 internationally, with 64% of foreign plants never being inspected.6 Even though the number of foreign inspections increased to 842 in 2015, 33% of foreign plants were still never inspected by the FDA.6 Domestically, inspections are frequently unannounced, whereas in foreign countries, this almost never occurs.7 As FDA guidance for inspectors specifies: “Preannounced inspections are necessary when conducting international inspections. This is due primarily to the potential waste of resources if the establishment is not operating or not producing the product in question, political sensitivities, availability of English speaking personnel, local holidays, etc. A request containing the proposed inspection dates is made to the foreign manufacturer either by direct contact or through an U.S. agent. Upon their agreement the inspection is conducted.”8 Prescheduling gives manufacturers time to clean their facilities, get their paperwork in order, and ensure that workers are on their best behavior.
What has been the result? Companies are not adhering to good manufacturing practices and falsifying, adjusting, or hiding data from the FDA. As inspections have recently increased, a glimpse into these chronic quality issues have come to light.4 Warning letters from the FDA have increased 5-fold from 2015 to 2018, going from 19 to 94 actions a year over that time. The FDA contends that this is not indicative of a growing problem in drug quality, and this is likely true. However, because so many issues are being found when these suboptimal preannounced inspections are conducted, it is likely that these manufacturers were supplying substandard medications to US citizens for years.4

Examples of Manufacturing Issues

In 2013, Ranbaxy pleaded guilty to failing to report that its drugs did not meet specifications and making intentionally false statements to the FDA, paying a $500 million penalty.9 Ranbaxy manufactured drugs that they knew tested out-of-specification, had unknown impurities, and would not maintain their expected shelf life. They sometimes recorded stability test results they never conducted.10 However, the FDA did not uncover these issues: a whistle blower tipped them off.9 Why was the FDA not more diligent? The World Health Organization alerted Ranbaxy Laboratories that their antiretroviral drug data looked fraudulent in 2004, causing the company to withdraw its antiretroviral drug applications.11
By 2015, 46 Indian manufacturing facilities were barred from shipping drugs to the US for one or more of the following: (1) alteration/manipulation of product and air quality data; (2) failure to review consumer complaints and hiding incident reports off site; (3) back dating quality testing; (4) altering/forging clinical trial data; (5) alteration of training records for quality assurance personnel or functions; (6) using data recording methods where data were preliminarily written down but could be overwritten, with the original data lost; (7) presence of unauthorized quality assurance stamps; and (8) performing multiple retesting of deviant samples and only recording the one that passed.12 Since that time, other manufacturers in India were found to have (1) shredded documents late at night before an FDA inspection, (2) allowed unsanitary manufacturing conditions, or (3) allowed “uncontrolled use of ‘trial’ injections during chromatographic testing” to achieve passing tests for drug batches or other reporting irregularities.13-16
Chinese-made drugs accounted for 8% of FDA generic approvals in 2018, up from 1% in 2015.17 A major current drug issue in the United States is the contamination of finished angiotensin II receptor blocker products (valsartan, losartan, irbesartan) with unacceptably high concentrations of potential carcinogens N-nitrosodimethylamine (NDMA) or N-nitrosodiethylamine.18 One of the major producers of valsartan and losartan API was Zhejiang Huahai Pharmaceuticals, a company with a history of quality issues.17,19 When inspected in 2017, the FDA found that they omitted from official test results that drug batches failed to meet US quality standards and instead recorded passing grades. In 2016, Chinese regulators asked the company to withdraw any applications to sell new drugs containing false or incomplete data. The company pulled applications in 3 drug classes.17,19 Ranitidine generics were recently found to have NDMA impurities as well.20
Issues with APIs in China first came to light in 2008 when patients receiving heparin in the United States suddenly started experiencing severe anaphylactoid reactions, with more than 100 cases resulting in death.21 After a viral disease began decimating the Asian pig population, an anticoagulant contaminant (over sulphated chondroitin) was intentionally but secretly added to heparin API in Asia as a replacement. The point in the supply chain where this occurred is not entirely clear. However, one manufacturer of the heparin API, Changzhou SPL Company, was inspected by FDA and received a warning letter after it was found to have used raw material (pig intestines) from uncertified farms; the tanks used in production or storing had unidentified material adhering to it, and testing for impurities was found to be insufficient.22
European generic manufacturers are not immune either. In 2016, FDA caught Italian drugmaker Facta Farmaceutici reporting only passing quality tests even though original reports indicated out-of-specification results for things like particulates in sterile drugs.23 On top of that, the FDA said that the inspector saw employees shredding records.23
This issue is not just limited to drugs being sold in the United States and could actually be worse internationally. The previous Drug Controller General of India, Dr G. N. Singh, was interviewed and asked about the ability of Indian manufacturers to meet FDA quality standards in 2014. He replied frankly, “If I have to follow US standards in inspecting facilities supplying to the Indian market, we will have to shut almost all of those.”24

Summary

Generic medications are a critical component of a financially sustainable health care system. There are honest generic manufacturers, but without independent verification, clinicians can rightfully be skeptical. Through a history of almost nonexistent quality verification of foreign drug manufacturers, the FDA allowed companies to produce poorly manufactured products and to ship them into the United States while guaranteeing physicians, pharmacists, and the US consumer that these products were interchangeable with other generic products and their brand name counterpart. Companies caught defrauding and endangering the US consumer are not permanently banned from shipping drugs into the United States; they are just required to raise their standards and, in some cases, to pay a fine. At the same time, US manufacturers were subject to much more frequent inspections that were unannounced and could not produce their products as cheaply, shuttering domestic plants and laying off US citizens. We run the risk of slaying the golden goose if we cannot secure our generic drug supply, and although the FDA has been making progress, their response is inadequate, and it has much left to do.

ORCID iD

References

1. Association for Accessible Medications. 2017 Generic drug access and savings in the US Report. https://accessiblemeds.org/resources/blog/2017-generic-drug-access-and-savings-us-report. Accessed September 13, 2019.
2. US Food and Drug Administration. Activities report of the Generic Drugs Program (FY 2018) monthly performance. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/activities-report-generic-drugs-program-fy-2018-monthly-performance. Published September 13, 2018. Accessed September 13, 2019.
3. US Food and Drug Administration. Generic drugs undergo rigorous FDA scrutiny. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm. Published October 8, 2014. Accessed September 13, 2019.
4. Pharma Reviews, US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, MD, and Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, MD, on the FDA’s continuing efforts to maintain its strong oversight of generic drug quality issues domestically and abroad. https://www.pharmareviews.in/statement-from-fda-commissioner-scott-gottlieb-m-d-and-director-of-fdas-center-for-drug-evaluation-and-research-janet-woodcock-m-d-on-the-fdas-continuing-efforts-to-maintain-it/. Published February 23, 2019. Accessed September 24, 2019.
5. Rehm D, Hamburg M. The safety of prescription drugs made outside the US. https://dianerehm.org/shows/2014-02-20/safety-prescription-drugs-made-outside-us. Published February 20, 2014. Accessed September 13, 2019.
6. United States Government Accountability Office. FDA has improved its Foreign Drug Inspection Program, but needs to assess the effectiveness and staffing of its foreign offices. https://www.gao.gov/assets/690/681689.pdf. Accessed September 13, 2019.
7. Inokon UM. Approaches to GMP inspection. CDER Small Business—Regulatory Education for Industry (REdl). https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM407991.pdf. Accessed September 13, 2019.
8. US Food and Drug Administration. Foreign inspections. Chapter 3: Establishment inspections. https://www.fda.gov/ICECI/Inspections/ForeignInspections/ucm113565.htm#311. Published April 23, 2015. Accessed September 13, 2019.
9. Eban K. Dirty medicine. Fortune Magazine. http://fortune.com/2013/05/15/dirty-medicine/. Published May 15, 2013. Accessed September 13, 2019.
10. US Department of Justice. Generic drug manufacturer Ranbaxy pleads guilty and agrees to pay $500 million to resolve false claims allegations, cGMP violations and false statements to the FDA. https://www.justice.gov/opa/pr/generic-drug-manufacturer-ranbaxy-pleads-guilty-and-agrees-pay-500-million-resolve-false. Published May 13, 2013. Accessed September 16, 2019.
11. US Food and Drug Administration. World Health Organization prequalifies Ranbaxy’s antiretrovirals. https://www.fdanews.com/articles/75605-world-health-organization-prequalifies-ranbaxy-s-antiretrovirals. Published August 23, 2005. Accessed September 13, 2019.
12. Brennan Z. FDA Form 483s from India: a deep dive into the problems. https://www.raps.org/regulatory-focus™/news-articles/2015/11/fda-form-483s-from-india-a-deep-dive-into-the-problems. Published November 9, 2015. Accessed September 13, 2019.
13. Palmer E. Hetero Labs plant hit with Form 483 for suspicious shredding of documents. Fierce Pharma. https://www.fiercepharma.com/manufacturing/hetero-labs-plant-hit-form-483-for-suspicious-shredding-documents. Published January 24, 2017. Accessed September 13, 2019.
14. Palmer E. Wockhardt US plant nailed by FDA in a warning letter. Fierce Pharma. https://www.fiercepharma.com/manufacturing/wockhardt-u-s-plant-nailed-by-fda-a-warning-letter. Published March 2, 2017. Accessed September 13, 2019.
15. Mehta D. US drug regulator clears Sun Pharma’s Halol plant. Bloomberg. https://www.bloombergquint.com/business/2018/06/12/us-drug-regulator-clears-sun-pharmas-halol-plant#gs.Phed1252. Published June 12, 2018. Accessed September 13, 2019.
16. Thacker T. US FDA flags issues at Sun Pharma’s Halol plant. Live Mint. https://www.livemint.com/Companies/NI7zYGVlhTdKlSFcz3v6dI/US-FDA-flags-issues-at-Sun-Pharmas-Halol-plant.html. Published February 24, 2018. Accessed September 13, 2019.
17. Edna A. How a tainted heart drug made in China slipped past the FDA. Bloomberg. https://www.bloomberg.com/news/features/2019-01-30/chinese-heart-drug-valsartan-recall-shows-fda-inspection-limits. Published January 30, 2019. Accessed September 13, 2019.
18. American College of Cardiology. Additional ARBs added to FDA recall list due to contamination. ACC News Story. https://www.acc.org/latest-in-cardiology/articles/2019/01/04/16/50/additional-arbs-added-to-fda-recall-list. Published January 4, 2019. Accessed September 13, 2019.
19. Hackett DW. Chinese vaccine producer faked data since 2014: FDA is working to ensure future valsartan active pharmaceutical ingredients are not at risk of N-nitrosodimethylamine (NDMA) formation. Precision Vaccinations. https://www.precisionvaccinations.com/fda-working%C2%A0-ensure-future-valsartan-active-pharmaceutical-ingredients-are-not-risk-n. Published August 7, 2018. Accessed September 13, 2019.
20. Woodcock J. Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine. Published September 13, 2019. Accessed September 16, 2019.
21. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Proc Rep. 2009;26:313-321.
22. US Food and Drug Administration. Warning letter Changzhou SPL Company. https://www.yourlawyer.com/pdf/Warning_Letter-04-21-08.pdf. Published April 21, 2008. Accessed September 13, 2019.
23. Palmer E. Italian sterile drugmaker Facta Farmaceutici slammed in FDA warning letter. Fierce Pharma. https://www.fiercepharma.com/manufacturing/italian-sterile-drugmaker-facta-farmaceutici-slammed-fda-warning-letter. Published February 2, 2017. Accessed September 13, 2019.
24. Dey S. If I follow US standards, I will have to shut almost all drug facilities: GN Singh. https://www.business-standard.com/article/economy-policy/if-i-follow-us-standards-i-will-have-to-shut-almost-all-drug-facilities-g-n-singh-114013000034_1.html. Published January 30, 2014. Accessed September 19, 2019.

Cite article

Cite article

Cite article

OR

Download to reference manager

If you have citation software installed, you can download article citation data to the citation manager of your choice

Share options

Share

Share this article

Share with email
EMAIL ARTICLE LINK
Share on social media

Share access to this article

Sharing links are not relevant where the article is open access and not available if you do not have a subscription.

For more information view the Sage Journals article sharing page.

Information, rights and permissions

Information

Published In

Article first published online: October 15, 2019
Issue published: March 2020

Keywords

  1. FDA
  2. drug safety
  3. generic drugs
  4. drug contamination

Rights and permissions

© The Author(s) 2019.
Request permissions for this article.
PubMed: 31615266

Authors

Affiliations

C. Michael White, PharmD, FCP, FCCP
University of Connecticut School of Pharmacy, Storrs, CT, USA

Notes

C. Michael White, Health Outcomes, Policy, and Evidence Synthesis Group, University of Connecticut School of Pharmacy, 69 North Eagleville Road, Storrs, CT 06269-3092, USA. Email: [email protected]

Metrics and citations

Metrics

Journals metrics

This article was published in Annals of Pharmacotherapy.

VIEW ALL JOURNAL METRICS

Article usage*

Total views and downloads: 9253

*Article usage tracking started in December 2016


Altmetric

See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores



Articles citing this one

Receive email alerts when this article is cited

Web of Science: 13 view articles Opens in new tab

Crossref: 16

  1. Research landscape analysis for quality in Pharma 4.0 era
    Go to citation Crossref Google Scholar
  2. Eye Drop Quality Issues: Can the FDA See This One Through?
    Go to citation Crossref Google Scholar
  3. A comprehensive review addressing the factors influencing generic drug...
    Go to citation Crossref Google Scholar
  4. Comparative safety of generic versus brand calcineurin inhibitors in s...
    Go to citation Crossref Google Scholar
  5. Criminal Action Against Drug Counterfeiters: Assessment of the FDA Off...
    Go to citation Crossref Google ScholarPub Med
  6. Countries Manufacturing Pharmaceuticals for the US Market: A 10-Year A...
    Go to citation Crossref Google ScholarPub Med
  7. Site-Specific and Country-of-Origin Labeling for Pharmaceutical Manufa...
    Go to citation Crossref Google ScholarPub Med
  8. Comparative efficacy of generic nifedipine versus brand‐name amlodipin...
    Go to citation Crossref Google Scholar
  9. Response to Letter to the Editor by Dr Robinson
    Go to citation Crossref Google Scholar
  10. Dangers of FDA Oversight of Clinical Trials in Developing Countries
    Go to citation Crossref Google Scholar
  11. Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the Shadow...
    Go to citation Crossref Google Scholar
  12. Persistencia al tratamiento con metformina de marca vs. genérica en mo...
    Go to citation Crossref Google Scholar
  13. Comparison of Discounted and Undiscounted Cash Prices for Cardiovascul...
    Go to citation Crossref Google Scholar
  14. Stress and strain on the U.S. drug supply: The intersection of shortag...
    Go to citation Crossref Google Scholar
  15. Current System of Overseeing Drug Trials in Developing Countries by th...
    Go to citation Crossref Google ScholarPub Med
  16. Looking Back at US Pharmacy’s Past to Help Discern Its Future
    Go to citation Crossref Google ScholarPub Med

Figures and tables

Figures & Media

Tables

View Options

View options

PDF/ePub

View PDF/ePub

Get access

Access options

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:


Alternatively, view purchase options below:

Purchase 24 hour online access to view and download content.

Access journal content via a DeepDyve subscription or find out more about this option.